Among 200 contemporary C. difficile isolates, there were no notable elevations in the in vitro omadacycline MIC, indicating a high level of activity towards C. difficile in comparison with commonly used antimicrobials for CABP and ABSSSI.

‎Show Gastro Girl, Ep A Microbiome Love Story: One Woman's Quest For Ulcerative Colitis Relief - May 2, 2023

Patients who experience CDI are vulnerable and require early diagnosis, clinical surveillance, and effective therapy to prevent complications and improve outcomes.

Characteristics of Hospitalized Adults 55 and Older With Clostridioides difficile Infection

Clinicians must remain vigilant in the prompt diagnosis and treatment of CDI in IBD patients. Corticosteroids, unnecessary antibiotics, and ongoing colonic inflammatory disease are modifiable risk factors. Improved infection control measures, newer IBD medications, and using effective CDI treatments …

Andrew Skinner, MD, reviews challenges in managing CDI, as well as the treatment guidelines from IDSA, SHEA, and ACG.

After an increase in Clostridioides difficile infections (CDI) until 2013 due to epidemic ribotypes such as 027 and 078, CDI incidence in Germany is now declining, as confirmed by recent epidemiological data. Despite this success through antimicrobial stewardship and hospital hygiene, the bur …

After an increase in iClostridioides difficile/i infections (CDI) until 2013 due to epidemic ribotypes such as 027 and 078, CDI incidence in Germany is now declining, as confirmed by recent epidemiological data. Despite this success through antimicrobial stewardship and hospital hygiene, the bur …

After an increase in Clostridioides difficile infections (CDI) until 2013 due to epidemic ribotypes such as 027 and 078, CDI incidence in Germany is now declining, as confirmed by recent epidemiological data. Despite this success through antimicrobial stewardship and hospital hygiene, the bur …

Clostridioides difficile infection (CDI) presents a major public health threat by causing frequently recurrent, life-threatening cases of diarrhea and intestinal inflammation. The ability of C. difficile to express antibiotic resistance and to form long-lasting spores makes the pathoge …

Clostridioides difficile infection (CDI) is the most lethal of the five CDC urgent public health treats, resulting in 12,800 annual deaths in the U...

Clostridioides difficile infection (CDI) is associated with high recurrence rates that have substantial effects on patients' quality of life. To investigate the risk factors and potential mechanisms contributing to recurrent CDI (rCDI), a total of 243 cases were enrolled in this study. The history o …

The PK/PD index and its target value of MNZ for CDI treatment was fecal AUC24/MIC ≥ 188. These findings may contribute to the effective clinical use of MNZ.

However, Clostridioides difficile (CDI) infection did not appear to affect outcomes, according to the study.

Clostridioides difficile infection (CDI) is associated with high recurrence rates that have substantial effects on patients' quality of life. To investigate the risk factors and potential mechanisms contributing to recurrent CDI (rCDI), a total of 243 cases were enrolled in this study. The history o …

The PK/PD index and its target value of MNZ for CDI treatment was fecal AUC24/MIC ≥ 188. These findings may contribute to the effective clinical use of MNZ.

Patients with primary #Cdiff infection have a ~20-25% chance of recurrent infection. #GITwitter #IDTwitter #guthealth pic.twitter.com/XxZ6cBN2aj— Microbiome Science (@MbiomeScience) May 24, 2023

A recent study from the University of Wisconsin-Madison suggests that interactions between gut bacteria …

#CDI is a costly 💲 illness, with hospitalizations being the primary cost driver. #GITwitter #IDTwitter #guthealth #Cdiff pic.twitter.com/9iPUAhjkTk— Microbiome Science (@MbiomeScience) May 21, 2023

New therapeutics have been FDA approved as well as real-world studies glean information about their efficacy.

While real-world studies on economic impact of rCDI in the USA suggested a high-cost burden, inconsistency in methodologies and results reporting warranted a component-based cost synthesis approach to estimate the annual medical cost burden of rCDI. Utilizing available literature, we estimated the a …

Exploring the potential of based live biotherapeutic products as a safe and effective therapy for Clostridiodes difficile. Read for more information.

Valerie Sanderson's family say she was "left in her own mess for an hour" in her bed.

To treat or not to treat: Clostridioides difficile infection (CDI) guidelines, diagnostic algorithms, and CDI reporting

Background: Clostridium difficile (C. difficile) is a common cause of hospital-acquired diarrhea. It is associated with significantly higher mortality and morbidity in addition to the cost-effec...

The Peggy Lillis Foundation’s Advocates Council is a nationwide network of individuals whose lives have been impacted by #cdiff Join the Advocates Council to use your voice and make a difference 👉https://t.co/n71VkuYlD5 pic.twitter.com/HFRxlGfwWG— Peggy Lillis Fund (@PeggyFund) May 17, 2023

Clostridioides difficile colonizes up to 30-40% of community-dwelling adults without causing disease [1][1], [2][2]. C. difficile infections (CDIs) are the leading cause of antibiotic-associated diarrhea in the U.S. [3][3], [4][4] and typically develop in individuals following disruption of the gut microbiota due to antibiotic or chemotherapy treatments [2][2]. Further treatment of CDI with antibiotics is not always effective and can lead to antibiotic resistance and recurrent infections (rCDI) [5][5], [6][6]. The most effective treatment for rCDI is the reestablishment of an intact microbiota via fecal microbiota transplants (FMTs) [7][7]. However, the success of FMTs has been difficult to generalize because the microbial interactions that prevent engraftment and facilitate the successful clearance of C. difficile are still only partially understood [8][8]. Here we show how microbial community-scale metabolic models (MCMMs) accurately predicted known instances of C. difficile colonization susceptibility or resistance. MCMMs provide detailed mechanistic insights into the ecological interactions that govern C. difficile engraftment, like cross-feeding or competition involving metabolites like succinate, trehalose, and ornithine, which differ from person to person. Indeed, three distinct C. difficile metabolic niches emerge from our MCMMs, two associated with positive growth rates and one that represents non-growth, which are consistently observed across 14,862 individuals from four independent cohorts. Finally, we show how MCMMs can predict personalized engraftment and C. difficile growth suppression for a probiotic cocktail (VE303) designed to replace FMTs for the treatment rCDI [9][9], [10][10]. Overall, this powerful modeling approach predicts personalized C. difficile engraftment risk and can be leveraged to assess probiotic treatment efficacy. MCMMs could be extended to better understand personalized engraftment of other opportunistic bacterial pathogens, beneficial probiotic organisms, or more complex microbial consortia. ### Competing Interest Statement The authors have declared no competing interest. [1]: #ref-1 [2]: #ref-2 [3]: #ref-3 [4]: #ref-4 [5]: #ref-5 [6]: #ref-6 [7]: #ref-7 [8]: #ref-8 [9]: #ref-9 [10]: #ref-10

The Clostridioides difficile study was presented at Digestive Disease Week in Chicago.

I am a healthy active older woman. On March 1, 2019 I had an explosive episode of diarrhea, out of the blue, no idea what caused it. The smell was indescribable, like nothing I had ever experienced in my long life. That was the beginning of a long saga I’ll …